Symbol not found

NASDAQ:IMUX   00:00AM GMT
0.00
0.00 (0.00%)
Earnings Announcements

Immunic Reports Second Quarter 2022 Financial Results

Published: 08/04/2022 11:16 GMT
Immunic Inc (IMUX) - Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update.
$88.1 Million in Cash and Cash Equivalents Expected to Fund Immunicinto Q4 of 2023.
Net Loss for Three Months Ended June 30, 2022 Was Approximately $21.9 Million, Or $0.72 per Basic and Diluted Share.
Q2 Earnings per Share View $-0.72, Revenue View $0.00 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.68

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.66

More details on our Analysts Page.